{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:31Z","timestamp":1791472111008,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Celltrion Inc."},{"name":"Deutsche Forschungsgemeinschaft Excellence Cluster Precision Medicine in Inflammation","award":["EXC2067"],"award-info":[{"award-number":["EXC2067"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03533-3","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:53:26Z","timestamp":1774857206000},"page":"2510-2526","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn\u2019s Disease: Insights from the Randomised, Placebo-Controlled, Phase\u00a03 LIBERTY-CD Trial"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct03945019","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2254-7771","authenticated-orcid":false,"given":"Stefan","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5762-5042","authenticated-orcid":false,"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7199-6851","authenticated-orcid":false,"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0894-8261","authenticated-orcid":false,"given":"Ae Lee","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-2432","authenticated-orcid":false,"given":"Dong-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2776-4708","authenticated-orcid":false,"given":"Young Nam","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6472-249X","authenticated-orcid":false,"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"8","key":"3533_CR1","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1080\/00365521.2020.1786852","volume":"55","author":"S Buhl","year":"2020","unstructured":"Buhl S, Dorn-Rasmussen M, Brynskov J, et al. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease. Scand J Gastroenterol. 2020;55(8):884\u201390. https:\/\/doi.org\/10.1080\/00365521.2020.1786852.","journal-title":"Scand J Gastroenterol"},{"issue":"9","key":"3533_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1097\/MCG.0000000000001774","volume":"57","author":"N Narula","year":"2023","unstructured":"Narula N, Wong E, Aruljothy A, et al. Baseline patient-reported symptoms less predictive than MM-SES-CD for endoscopic remission in Crohn\u2019s disease. J Clin Gastroenterol. 2023;57(9):913\u20139. https:\/\/doi.org\/10.1097\/MCG.0000000000001774.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"3533_CR3","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/apt.13139","volume":"41","author":"JF Colombel","year":"2015","unstructured":"Colombel JF, Reinisch W, Mantzaris GJ, et al. Randomised clinical trial: deep remission in biologic and immunomodulator naive patients with Crohn\u2019s disease - a SONIC post hoc analysis. Aliment Pharmacol Ther. 2015;41(8):734\u201346. https:\/\/doi.org\/10.1111\/apt.13139.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3533_CR4","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1136\/gutjnl-2012-304094","volume":"63","author":"F Cornillie","year":"2014","unstructured":"Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014;63(11):1721\u20137. https:\/\/doi.org\/10.1136\/gutjnl-2012-304094.","journal-title":"Gut"},{"issue":"7","key":"3533_CR5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/ecco-jcc\/jjaa242","volume":"15","author":"ECL Wong","year":"2021","unstructured":"Wong ECL, Buffone E, Lee SJ, et al. End of induction patient-reported outcomes predict clinical remission but not endoscopic remission in Crohn\u2019s disease. J Crohns Colitis. 2021;15(7):1114\u20139. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa242.","journal-title":"J Crohns Colitis"},{"key":"3533_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2147\/CEG.S360248","volume":"16","author":"JW Clinton","year":"2023","unstructured":"Clinton JW, Cross RK. Personalized treatment for Crohn\u2019s disease: current approaches and future directions. Clin Exp Gastroenterol. 2023;16:249\u201376. https:\/\/doi.org\/10.2147\/CEG.S360248.","journal-title":"Clin Exp Gastroenterol"},{"issue":"10114","key":"3533_CR7","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","volume":"390","author":"JF Colombel","year":"2017","unstructured":"Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn\u2019s disease (CALM): a multicentre, randomised, controlled phase\u00a03 trial. Lancet. 2017;390(10114):2779\u201389. https:\/\/doi.org\/10.1016\/S0140-6736(17)32641-7.","journal-title":"Lancet"},{"issue":"1","key":"3533_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"RC Ungaro","year":"2020","unstructured":"Ungaro RC, Yzet C, Bossuyt P, et al. Deep remission at 1\u00a0year prevents progression of early Crohn\u2019s disease. Gastroenterology. 2020;159(1):139\u201347. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039.","journal-title":"Gastroenterology"},{"issue":"9","key":"3533_CR9","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.18553\/jmcp.2020.26.9.1138","volume":"26","author":"M Alhazami","year":"2020","unstructured":"Alhazami M, Pontinha VM, Patterson JA, Holdford DA. Medication adherence trajectories: a systematic literature review. J Manag Care Spec Pharm. 2020;26(9):1138\u201352. https:\/\/doi.org\/10.18553\/jmcp.2020.26.9.1138.","journal-title":"J Manag Care Spec Pharm"},{"key":"3533_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.2147\/CEOR.S59339","volume":"6","author":"Y Li","year":"2014","unstructured":"Li Y, Zhou H, Cai B, et al. Group-based trajectory modeling to assess adherence to biologics among patients with psoriasis. Clinicoecon Outcomes Res. 2014;6:197\u2013208. https:\/\/doi.org\/10.2147\/CEOR.S59339.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"suppl 8","key":"3533_CR11","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ueg2.12295","volume":"11","author":"S Schreiber","year":"2023","unstructured":"Schreiber S, Feagan BG, Sands BE, et al. Group-based trajectory modeling to identify response patterns to ozanimod treatment in patients with ulcerative colitis. UEG J. 2023;11(suppl 8):483\u20134. https:\/\/doi.org\/10.1002\/ueg2.12295.","journal-title":"UEG J"},{"issue":"suppl 8","key":"3533_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ueg2.12294","volume":"10","author":"S Schreiber","year":"2022","unstructured":"Schreiber S, Peyrin-Biroulet L, Hibi T, et al. Trajectory modelling to identify different types of individual response to therapy: a post hoc analysis from the SELECTION study. UEG J. 2022;10(suppl 8):459. https:\/\/doi.org\/10.1002\/ueg2.12294.","journal-title":"UEG J"},{"key":"3533_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/ueg2.12461","volume":"11","author":"S Schreiber","year":"2023","unstructured":"Schreiber S, Ostanin D, Cheng J, et al. Machine learning-based precision medicine approach identifies specific responder sub-populations by dynamic clustering of pro data: post hoc analysis of VARSITY dataset. UEG J. 2023;11:919\u201340. https:\/\/doi.org\/10.1002\/ueg2.12461.","journal-title":"UEG J"},{"issue":"7","key":"3533_CR14","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1053\/j.gastro.2021.02.068","volume":"160","author":"S Schreiber","year":"2021","unstructured":"Schreiber S, Ben-Horin S, Leszczyszyn J, et al. Randomized controlled trial: subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 2021;160(7):2340\u201353. https:\/\/doi.org\/10.1053\/j.gastro.2021.02.068.","journal-title":"Gastroenterology"},{"issue":"5","key":"3533_CR15","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1053\/j.gastro.2024.05.006","volume":"167","author":"SB Hanauer","year":"2024","unstructured":"Hanauer SB, Sands BE, Schreiber S, et al. Subcutaneous infliximab (CT-P13) as maintenance therapy for inflammatory bowel disease: 2 randomized phase\u00a03 trials. Gastroenterology. 2024;167(5):919\u201333. https:\/\/doi.org\/10.1053\/j.gastro.2024.05.006.","journal-title":"Gastroenterology"},{"key":"3533_CR16","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1146\/annurev.clinpsy.121208.131413","volume":"6","author":"DS Nagin","year":"2010","unstructured":"Nagin DS, Odgers CL. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol. 2010;6:109\u201338. https:\/\/doi.org\/10.1146\/annurev.clinpsy.121208.131413.","journal-title":"Annu Rev Clin Psychol"},{"issue":"1","key":"3533_CR17","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ecco-jcc\/jjad130","volume":"18","author":"S Schreiber","year":"2024","unstructured":"Schreiber S, Danese S, Dignass A, et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: International Delphi Consensus Recommendations. J Crohns Colitis. 2024;18(1):91\u2013105. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad130.","journal-title":"J Crohns Colitis"},{"issue":"1","key":"3533_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12876-021-01883-6","volume":"21","author":"O Alipour","year":"2021","unstructured":"Alipour O, Gualti A, Shao L, Zhang B. Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNF\u03b1 in inflammatory bowel disease. BMC Gastroenterol. 2021;21(1):312. https:\/\/doi.org\/10.1186\/s12876-021-01883-6.","journal-title":"BMC Gastroenterol"},{"issue":"suppl 1","key":"3533_CR19","doi-asserted-by":"publisher","first-page":"i2061","DOI":"10.1093\/ecco-jcc\/jjae190.1296","volume":"19","author":"SW Schreiber","year":"2025","unstructured":"Schreiber SW, Clemow DB, Yu G, et al. Identification of responder subpopulations in moderately-to-severely active Crohn\u2019s disease patients treated with mirikizumab: results from the VIVID-1 study. J Crohns Colitis. 2025;19(suppl 1):i2061\u20132. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae190.1296.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"3533_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/MPG.0000000000003370","volume":"74","author":"A Chen","year":"2022","unstructured":"Chen A, Stein R, Baldassano RN, Huang J. Learning longitudinal patterns and subtypes of pediatric Crohn disease treated with infliximab via trajectory cluster analysis. J Pediatr Gastroenterol Nutr. 2022;74(3):383\u20138. https:\/\/doi.org\/10.1097\/MPG.0000000000003370.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"3533_CR21","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.cgh.2013.06.019","volume":"12","author":"JF Colombel","year":"2014","unstructured":"Colombel JF, Rutgeerts PJ, Sandborn WJ, et al. Adalimumab induces deep remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2014;12(3):414-422 e5. https:\/\/doi.org\/10.1016\/j.cgh.2013.06.019.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"suppl 1","key":"3533_CR22","doi-asserted-by":"publisher","first-page":"i379","DOI":"10.1093\/ecco-jcc\/jjab232.504","volume":"16","author":"M Allez","year":"2022","unstructured":"Allez M, Lewis JD, Hanauer SB, et al. Impact of moderate-to-severe endoscopic disease criteria on endoscopic response, endoscopic remission, and deep remission in patients receiving ustekinumab or adalimumab in the SEAVUE study. J Crohns Colitis. 2022;16(suppl 1):i379\u201380. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab232.504.","journal-title":"J Crohns Colitis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03533-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03533-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:49Z","timestamp":1780116709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03533-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3533"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03533-3","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"7 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors disclose the following: Stefan Schreiber \u2013 advisory committee\/board member, AbbVie, Amgen, Arena, Biogen, BMS, Celgene, Celltrion, Falk, Ferring, Fresenius, Galapagos, Gilead, IMAB, Janssen, Lilly, MSD, Mylan, Pfizer, Protagonist, Provention Bio, Sandoz\/Hexal, Takeda, Theravance, and UCB; lecturer, Hikma; stockholder of CONARIS AG. Bruce E. Sands \u2013 consulting fees from Abbvie, Adiso Therapeutics, Agomab, Alimentiv, Amgen, AnaptysBio, Arena Pharmaceuticals, Artugen Therapeutics, AstraZeneca, Biolojic Design, Biora Therapeutics, Boehringer Ingelheim, Boston Pharmaceuticals, Calibr, Celgene, Celltrion, ClostraBio, Equillium, Enthera, Envied Biosciences, Evommune, Ferring, Fresenius Kabi, Fiat, Galapagos, Genentech (Roche), Gilead Sciences, GlaxoSmithKline, Gossamer Bio, Imhotex,\u00a0Index Pharmaceuticals, Innovation Pharmaceuticals, Inotrem, Kaleido, Kallyope, Merck & Co., Microbiotica, Mitsubishi Tanabe, Mobius Care, Morphic Therapeutics, MRM Health, Nexus Therapeutics, Nimbus Discovery, Odyssey Therapeutics, Palisade Bio, Progenity, Prometheus Biosciences, Prometheus Laboratories, Protagonist Therapeutics, Q32 Bio, Rasayana Therapeutics, Recludix Therapeutics, Reistone Biopharma, Sanofi, Sorriso Therapeutics, Spyre Therapeutics, Surrozen, Target RWE, Teva, TLL Pharmaceutical, Tr1X, Union Therapeutics, and Ventyx Biosciences; consulting and speaking fees, from Abivax; consulting and speaking fees, and other support from Lilly; research grants, consulting and speaking fees and other support from Bristol Myers Squibb, Eli Lilly & Company, Janssen, Pfizer, and Takeda; research grants and consulting fees from Janssen; and stock\/stock options from Ventyx Biopharma. Silvio Danese \u2013 consultant fees from AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB, Vial, and Vifor; lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals, Gilead, Janssen, Mylan, Pfizer, and Takeda. Edward V. Jr. Loftus \u2013 consultant fees from AbbVie, Abivax, Astellas, Avalo Therapeutics, Biocon, Bristol Myers Squibb, Eli Lilly, Fresenius Kabi, Genentech, Gilead, Iota Biosciences, Iterative Health, Janssen, Merck, Morphic, Ono Pharma, Spyre Therapeutics, Takeda, and TR1X Bio; research support from AbbVie, Gilead, Janssen, Merck, and TR1X Bio; shareowner of Exact Sciences and Moderna. Ae Lee Jeong, Dong-Hyeon Kim, and Young Nam Lee are employees of Celltrion Inc. Dong-Hyeon Kim and Young Nam Lee are stockholders of Celltrion Inc. Jean-Fr\u00e9d\u00e9ric Colombel \u2013 research grants from AbbVie, Janssen Pharmaceuticals, Takeda, Prometheus, and Bristol Myers Squibb; lecturer \u2013 AbbVie and Takeda; consultant fees from AbbVie, Amgen, AnaptysBio, Allergan, Arena Pharmaceuticals, Astellas, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Celltrion, Eli Lilly, Envision Pharma, Ferring Pharmaceuticals, Galmed Research, GlaxoSmithKline, Genentech (Roche), Janssen Pharmaceuticals, Kaleido Biosciences, Immunic, Iterative Scopes, Merck, Landos, Microba Life Science, Novartis, Otsuka Pharmaceutical, Pfizer, Protagonist Therapeutics, Sanofi, Sun, Takeda, TiGenix, and Vifor; stock options, Intestinal Biotech Development.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was performed in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. Prior to study initiation, the study protocol was approved by an independent ethics committee or institutional review board at each participating site. The full list of study sites is reported in the primary manuscript supplementary materials [\n                      \n                      ]. All participants provided written informed consent prior to enrolment in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}